APREA THERAPEUTICS INC (APRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.79-1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APRE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
APRE — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-07-23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), Nasdaq has dete…
Why it matters: New data will show how well APR-1051 is working in patients. Positive results could boost confidence in the drug's potential.
Supportive ifAprea shares good clinical data from the ACESOT-1051 trial at a meeting in Q4 2026.
Worry ifThe clinical data shows no clear improvement or bad results.
Why it matters: Faster enrollment indicates strong interest and could lead to quicker results. This is key for the trial's success.
Supportive ifEnrollment reaches 6 to 10 patients per month by Q4 2026.
Worry ifEnrollment is below 6 patients each month. This may show some problems.
Why it matters: Completing dose escalation is key. It helps us understand APR-1051's safety and effectiveness.
Supportive ifDose escalation in ACESOT-1051 is completed by Q2 2027.
Worry ifDose escalation is delayed beyond Q2 2027.
Why it matters: Updates on cash will show if Aprea can fund its trials and operations until 2028.
Watch forQ2 earnings report shows cash and equivalents above $46.5 million.
Also watch forQ2 earnings report shows cash and equivalents below $46.5 million.
Why it matters: Fixing the Nasdaq listing issue is key. It helps keep investor trust and market access.
Supportive ifAprea submits a plan to Nasdaq that is accepted and meets compliance requirements.
Worry ifNasdaq sends a delisting notice. This is due to not fixing the problem.
Why it matters: Fixing this issue is important for Aprea. It helps keep its stock listing and investor trust.
Supportive ifA public announcement says Aprea has fixed the Nasdaq listing issue.
Worry ifNasdaq keeps sending notices about problems. There is no solution yet.
Why it matters: Not following rules could lead to delisting. This would hurt investor confidence and stock trading.
Worry ifThe stock price regains compliance with the $1.00 minimum bid price requirement.
Less concerning ifThe stock price is still below $1.00. This leads to more Nasdaq delisting warnings.
Why it matters: Looking into combination therapies for ATRN-119 may create new treatment options. Good news could help the company's growth.
Supportive ifA press release shares new studies or partnerships. These are for ATRN-119 combination therapies.
Worry ifNo new news or partnerships for ATRN-119 means there is no progress.
Why it matters: The company received a notice about not meeting the $1.00 share price rule. This affects its listing and investor confidence.
Worry ifA press release says Aprea has met Nasdaq's minimum bid price requirement again.
Less concerning ifNasdaq sent more alerts about ongoing problems with listing rules.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $834 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,424 loss on $10,000 · 64.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.